Clinical Colorectal Cancer

Aims & Scope

Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers.

Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers.

The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers.

Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	3.2
2024	3.30

SJR (SCImago Journal Rank)

Year	Value
2024	1.187

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	67

Journal Rank

Year	Value
2024	3621

Journal Citation Indicator

Year	Value
2024	614

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer

  Citation: 383

  Authors: Bengt, Göran, David, Nicholas, Arnaud, Hans-Joachim, Kjell-Magne, Fernando

• Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality

  Citation: 248

  Authors: Veronica, Ana Paula, Luiz Claudio, Carlos Gil

• Bowel Function 14 Years After Preoperative Short-Course Radiotherapy and Total Mesorectal Excision for Rectal Cancer: Report of a Multicenter Randomized Trial

  Citation: 235

  Authors: Tina Yen-Ting, Lisette M., Remi A., Elma, Søren, Corrie A.M., Cornelis J.H.

• Changing Patterns of Bone and Brain Metastases in Patients with Colorectal Cancer

  Citation: 155

  Authors: Mark L., Neal J., André, Hao, Steven J.

• Clinical Management of Oxaliplatin-Associated Neurotoxicity

  Citation: 151

  Authors: Axel

• Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer

  Citation: 150

  Authors: Steven J., R. Katherine, Steve, Shawn M., Denis A., Leon W.M.M., W. Jeffrey, Maryann, Jonathan D., John P., Nancy L., Ann, André, Elin, Hao, James C., Louis M., Neal J.

• Dihydropyrimidine Dehydrogenase Deficiency, a Pharmacogenetic Syndrome Associated with Potentially Life-Threatening Toxicity Following 5-Fluorouracil Administration

  Citation: 142

  Authors: Hany, Robert

• Early-onset Colorectal Cancer is Distinct From Traditional Colorectal Cancer

  Citation: 138

  Authors: Heather, Doron, Jonathan S., Xi E., Rhonda, Manish A.

• Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti—Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer

  Citation: 125

  Authors: Tara Beers, Aarati, Axel

• Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

  Citation: 119

  Authors: Daniel J., Todd, Maureen, J. Randolph, Neal J., Jordan, Edith, Ildiko, Robert, Rafael G.

---